TELA news

Latest 3 stories · newest Oct 5, 2026

TELA

TELA Bio received FDA clearance for its Liora Monofilament Scaffold, expanding its product portfolio for soft tissue reconstruction. This marks the first full resorbable synthetic product developed in its ISO 8 certified cleanroom.

Regulatory Oct 5, 2026 sentiment +0.70 SEC filing ↗

TELA

TELA Announces COO and CFO Transition, Pricing Plan

TELA Bio announced a transition of leadership roles and implemented a strategic cost reduction initiative effective August 31, 2026, planning to execute a targeted headcount reduction of approximately 20%.

Leadership|Restructuring Aug 31, 2026 sentiment -0.50 SEC filing ↗

TELA

TELA Bio amends 2019 equity plan, increasing share limit to 10.9M

TELA Bio's board and stockholders approved Amendment No. 2 to the company's 2019 Equity Incentive Plan, raising the maximum shares available for awards and implementing stricter repricing prohibitions. The amendment enhances governance controls while expanding the equity compensation pool available …

Regulatory Jun 11, 2026 sentiment +0.10 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same TELA feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/TELA/newsSTART FREE